Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Clinical and Paraclinical Characterization of Osseous Anomalies of the Long Bones of Patients With Klippel Trénaunay Syndrome

NCT07060703 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-09-12
Last updated
2025-07-11

Condition(s) studied

Radiological Bone Phenotype Description of Patients With KTS ( Klippel-Trénaunay Syndrome )

Investigational drug(s) / intervention(s)

Osteodensitometry

Osteodensitometry: exploration of long bones using non-invasive Guided Wave Velocity (GWV) technology. comparison of ultrasound parameters (cortical thickness and porosity, among others) with BMD values (spine, right and left femoral necks) obtained by DXA. \[Time Frame: 20 MIN\]

Study summary

Clinical and paraclinical characterization of osseous anomalies of the long bones of patients with Klippel Trénaunay syndrome

Eligibility

Sex
ALL
Min age
7 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Vascular malformation such as Klippel-Trénaunay syndrome or Capillary malformations (CM) + venous malformations (VM) +/- Lymphatic malformations (LM) + limb overgrowth according to ISSVA (International Society for the Study of Vascular Anomalies) classification. * Signature of study consent by subject of legal age or by 2 legal guardians for minors Patient affiliated to a social security scheme or beneficiary of such a scheme * Age greater than or equal to 7 years Exclusion Criteria: Pregnant or breast-feeding woman Protected person \-

Primary outcome measure(s)

  • Quantification of limb-length asymmetry on lower-limb telemetry (absolute values, in mm) compared with the contralateral side — 20 minutes
    The assessment of bone damage includes an X-ray of a weight-bearing pelvis and limb telemetry to detect any limb length abnormalities.

Trial sites (1)

FacilityCityRegionStatus
Chu Grenoble Alpes La Tronche France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07060703 on ClinicalTrials.gov ↗ ← All trials in France